Akston Biosciences Corporation (AXTN)

Akston Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	2.91	1.89	0.81
Cash & Cash Equivalents	2.91	1.89	0.81
Cash Growth	-	134.76%	-
Receivables	0.01	0.36	0.16
Inventory	2.3	0.69	7.48
Other Current Assets	0.18	0	0
Total Current Assets	5.4	2.95	8.44
Property, Plant & Equipment	-	1.55	2.95
Goodwill and Intangibles	-	5.52	1.48
Other Long-Term Assets	-	0.36	0.36
Total Long-Term Assets	-	7.43	4.8
Total Assets	-	10.37	13.24
Accounts Payable	-	1.79	2.59
Deferred Revenue	-	0.07	10.28
Current Debt	-	0.76	0.86
Other Current Liabilities	4.17	0.95	0.48
Total Current Liabilities	4.17	3.58	14.22
Long-Term Debt	-	10.33	5.82
Other Long-Term Liabilities	-	1.09	4.63
Total Long-Term Liabilities	-	11.42	10.46
Total Liabilities	-	15	24.67
Total Debt	10.91	11.1	6.68
Debt Growth	-	66.05%	-
Retained Earnings	-	-62.04	-65.84
Shareholders' Equity	-13	-4.63	-11.44
Net Cash (Debt)	-8	-9.21	-5.88
Working Capital	1.24	-0.63	-5.77

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).